Orchestra BioMed Holdings (OBIO) Cash from Operations (2021 - 2026)
Orchestra BioMed Holdings (OBIO) reported Cash from Operations of 22168000.0 for Q1 2026, down 33.41% year-over-year from 33292072.31 in Q1 2025, and down 876.56% on a QoQ basis from 2270000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 6 years of Cash from Operations data on file, last reported at 22168000.0 in Q1 2026.
- Quarterly Cash from Operations fell 33.41% year-over-year to 22168000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 54515000.0 (down 0.84% YoY) and the FY2025 annual result came in at 48963000.0, up 3.15% from the prior year.
- Cash from Operations declined to 22168000.0 in Q1 2026 per OBIO's latest filing, from 2270000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2270000.0 in Q4 2025 and bottomed at 22168000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 10974000.0 (2023), against an average of 11594411.76.
- The widest annual swing landed in 2022, when Cash from Operations sank 30224.26%; it then jumped 83.23% in 2025.
- Tracing OBIO's Cash from Operations over 5 years: stood at 8744000.0 in 2022, then slipped by 25.5% to 10974000.0 in 2023, then fell by 23.36% to 13538000.0 in 2024, then jumped by 83.23% to 2270000.0 in 2025, then plunged by 876.56% to 22168000.0 in 2026.
- Per Business Quant, the three latest OBIO Cash from Operations figures stand at 22168000.0 (Q1 2026), 2270000.0 (Q4 2025), and 14550000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -22.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.17 Mn |
| Mar 31, 2026 | -22.17 Mn |
| Dec 31, 2025 | -2.27 Mn |
| Dec 31, 2025 | -2.27 Mn |
| Sep 30, 2025 | -14.55 Mn |
| Sep 30, 2025 | -14.55 Mn |
| Jun 30, 2025 | -15.53 Mn |
| Jun 30, 2025 | -15.53 Mn |
| Mar 31, 2025 | -16.62 Mn |
| Mar 31, 2025 | -16.62 Mn |
| Dec 31, 2024 | -13.54 Mn |
| Dec 31, 2024 | -13.54 Mn |
| Sep 30, 2024 | -13.70 Mn |
| Sep 30, 2024 | -13.70 Mn |
| Jun 30, 2024 | -10.21 Mn |
| Jun 30, 2024 | -10.21 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -10.97 Mn |
| Dec 31, 2023 | -10.97 Mn |
| Sep 30, 2023 | -10.28 Mn |
| Sep 30, 2023 | -10.28 Mn |
| Jun 30, 2023 | -10.49 Mn |
| Jun 30, 2023 | -10.49 Mn |
| Mar 31, 2023 | -14.38 Mn |
| Mar 31, 2023 | -14.38 Mn |
| Dec 31, 2022 | -8.74 Mn |
| Dec 31, 2022 | -8.74 Mn |
| Sep 30, 2022 | -7.26 Mn |
| Sep 30, 2022 | -7.26 Mn |
| Jun 30, 2022 | -7.97 Mn |
| Jun 30, 2022 | -7.97 Mn |
| Mar 31, 2022 | -5.32 Mn |
| Mar 31, 2022 | -5.32 Mn |
| Dec 31, 2021 | -28,835.00 |
| Dec 31, 2021 | -28,835.00 |
| Sep 30, 2021 | -128,010.00 |
| Sep 30, 2021 | -128,010.00 |
| Jun 30, 2021 | -39,143.00 |
| Jun 30, 2021 | -39,143.00 |
| Mar 31, 2021 | -76,374.00 |
| Mar 31, 2021 | -76,374.00 |